About Our Pipeline

CytomX is advancing a pipeline of Probody™ therapeutics to treat cancer.

Our innovative pipeline is focused on the development of next-generation therapies in a diverse set of modalities: Probody cancer immunotherapies, Probody drug conjugates (PDCs), T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Each of these therapeutic classes has shown incredible potential, with unique advantages based on treatment scenario, bringing forth new options for powerful drugs that have previously been limited by toxicity concerns.

Read about our pipeline in BioCentury Innovations.